Author(s)

Yuxuan Gao, Zongheng He, Mengshan Hu

Corresponding Author

Yuxuan Gao

ABSTRACT

Paclitaxel drug is vital breast cancer treatment, which have been extensively studied in clinical trials worldwide. Paclitaxel dose Optimization and evaluation in combination regimens are the main concerning problem. The efficacy of chemotherapy drugs may be mainly determined by the genotype of the tumor cells. The mutated p53 gene may lead to chemotherapy resistance. Although paclitaxel is widely effectively used in human tumor xenografts, p53-containing tumor cells were obviously more sensitive to treatment with this drug than p53-deficient tumor cells. Maximum tolerated dose (MTD) of first-line gemcitabine and albumin-bound paclitaxel in metastatic pancreatic cancer provided efficacy and safety data in preclinical trials. This paper reviews the therapeutic progress and clinical application of paclitaxel.

KEYWORDS

Paclitaxel (Taxol), P53 target, Preclinical trials, cancer, Homotope Proteolysis-Targeting Chimeras (HPROTAC)